Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

or on the link below. Prostate-specific antigen (PSA) is both a blessing and a curse for prostate cancer. It is a blessing because it makes prostate cancer one of the few cancers with a reliable serum ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

For decades, it has been known that prostate specific antigen ‒ or PSA ‒ tests are a flawed way to diagnose prostate cancer. Many men have a high PSA without having cancer. Others have low PSA that ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Compared to White men, Black men have a higher risk of developing prostate cancer. Additionally, Black men have a greater risk than White men of prostate cancer mortality. Asian men have a lower risk ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...